导航

| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -1.10% | 2631/4773 |
| 近一周 | -1.89% | 3692/5467 |
| 近一月 | -5.54% | 2465/5421 |
| 近一季 | -7.84% | 2494/5238 |
| 近半年 | -1.45% | 1947/4931 |
| 近一年 | 1.16% | 2325/4400 |
| 近两年 | 49.18% | 1504/2954 |
| 近三年 | 30.75% | 1048/2253 |
| 成立以来 | 49.67% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.70% 3355/4961 |
12.85% 2106/5312 |
- - |
- - |
| 2025 | 20.81% 2087/4813 |
-1.01% 2534/3635 |
2.32% 1652/4076 |
18.97% 2214/4524 |
0.26% 2096/4813 |
| 2024 | 17.51% 681/3463 |
2.82% 694/2808 |
-1.15% 951/3014 |
17.69% 1141/3129 |
-1.76% 1817/3463 |
| 2023 | -8.30% 996/2656 |
4.63% 902/2280 |
-3.89% 953/2385 |
-2.50% 685/2515 |
-6.47% 1790/2655 |
| 2022 | -18.96% 782/2207 |
-13.99% 887/1919 |
7.22% 510/2016 |
-13.74% 965/2113 |
1.89% 1099/2208 |
| 2021 | -1.35% 795/1822 |
-2.82% 709/1255 |
4.89% 839/1330 |
-4.98% 758/1466 |
1.86% 776/1822 |
| 2020 | 35.04% 425/1250 |
-9.52% 684/1028 |
14.15% 567/1067 |
14.70% 266/1164 |
13.99% 312/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 国联安沪深300ETF VS. 长安沪深300非周期A(740101) |